Skip to main content Deutsch

Sortiert nach PI

Sorry, this content is only available in German!

Publikationen - sortiert nach Principle Investigator

Medical NeuroScience Cluster Publications by Berger, Thomas

Last year | Last five years | All

2024 Original Articles

  • Steinmaurer A, Riedl C, König T, Testa G, Köck U, Bauer J, Lassmann H, Höftberger R, Berger T, Wimmer I, Hametner S (2024) The relation between BTK expression and iron accumulation of myeloid cells in multiple sclerosis Brain Pathol, 34(5): e13240

2023 Original Articles

  • Krajnc N, Schmidbauer V, Leinkauf J, Haider L, Bsteh G, Kasprian G, Leutmezer F, Kornek B, Rommer P, Berger T, Lassmann H, Dal-Bianco A, Hametner S (2023) Paramagnetic rim lesions lead to pronounced diffuse periplaque white matter damage in multiple sclerosis Mult Scler, 29(11-12): 1406-1417
  • Krajnc N, Dal-Bianco A, Leutmezer F, Kasprian G, Pemp B, Kornek B, Berger T, Rommer P, Hametner S, Lassmann H, Bsteh G (2023) Association of paramagnetic rim lesions and retinal layer thickness in patients with multiple sclerosis Mult Scler, 29(3): 374-384

2022 Original Articles

  • Hametner S, Silvaieh S, Thurnher M, Dal-Bianco A, Cetin H, Ponleitner M, Zebenholzer K, Pemp B, Trattnig S, Rössler K, Berger T, Lassmann H, Hainfellner J, Bsteh G (2022) A case of primary optic pathway demyelination caused by oncocytic oligodendrogliopathy of unknown origin Acta Neuropathologica Communications, 10 (1): 160
  • Krajnc N, Bsteh G, Kasprian G, Zrzavy T, Kornek B, Berger T, Leutmezer F, Rommer P, Lassmann H, Hametner S, Dal-Bianco A (2022) Peripheral Hemolysis in Relation to Iron Rim Presence and Brain Volume in Multiple Sclerosis Front Neurol, 13: 928582

2022 Reviews

  • Höftberger R, Lassmann H, Berger T, Reindl M (2022) Pathogenic autoantibodies in multiple sclerosis — from a simple idea to a complex concept Nat Rev Neurol, : 18(11):681-688

2021 Original Articles

  • Altmann P, Leithner K, Leutmezer F, Monschein T, Ponleitner M, Stattmann M, Rommer P, Zrzavy T, Zulehner G, Berek K, Berger T, Bsteh G (2021) Sexuality and Multiple Sclerosis: Patient and Doctor Perspectives JSM, 18 (4): 743-749
  • Altmann P, Leutmezer F, Leithner K, Monschein T, Ponleitner M, Stattmann M, Rommer P, Zrzavy T, Zulehner G, Berek K, Berger T, Bsteh G (2021) Predisposing Factors for Sexual Dysfunction in Multiple Sclerosis Front Neurol, 12: 618370
  • Monschein T, Schestak C, Schillerwein-Kral C, Leutmezer F, Berger T, Bsteh G, Seidel S (2021) Restless Legs Syndrome in Multiple Sclerosis: Risk factors and effect on sleep quality – a case-control study Mult Scler Relat Disord., 51: 102916
  • Dal-Bianco A, Schranzer R, Grabner G, Lanzinger M, Kolbrink S, Pusswald G, Altmann P, Ponleitner M, Weber M, Kornek B, Zebenholzer K, Schmied C, Berger T, Lassmann H, Trattnig S, Hametner S, Leutmezer F, Rommer P (2021) Iron Rims in Patients With Multiple Sclerosis as Neurodegenerative Marker? A 7-Tesla Magnetic Resonance Study Front Neurol, 12: 632749
  • Bsteh G, Hegen H, Altmann P, Auer M, Berek K, Di Pauli F, Leutmezer F, Rommer P, Wurth S, Zinganell A, Zrzavy T, Deisenhammer F, Berger T (2021) Retinal layer thinning predicts treatment failure in relapsing multiple sclerosis Eur J Neurol, 28 (6): 2037-2045
  • Zrzavy T, Daniels E, Stuka N, Weber D, Winkelmann A, Rauschka H, Hecker M, Aboulenein-Djamshidian F, Meister S, Leutmezer F, Berger T, Bsteh G, Zettl UK, Rommer P (2021) Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis Therapeutic Advances in Chronic Disease, 12: 204062232110243
  • Ricken G, Zrzavy T, Macher S, Altmann P, Troger J, Falk K, Kiefer A, Fichtenbaum A, Mitulovic G, Kubista H, Wandinger K, Rommer P, Bartsch T, Berger T, Weber J, Leypoldt F, Höftberger R (2021) Autoimmune Global Amnesia as Manifestation of AMPAR Encephalitis and Neuropathologic Findings Neurol Neuroimmunol Neuroinfl, 8 (4): e1019
  • Macher S, Milenkovic I, Zrzavy T, Höftberger R, Seidel S, Berger-Sieczkowski E, Berger T, Rommer P, Wiest G (2021) Ocular Motor Abnormalities in Anti-IgLON5 Disease Front Immunol, 12
  • Zrzavy T, Endmayr V, Bauer J, Macher S, Mossaheb N, Schwaiger C, Ricken G, Winklehner M, Glatter S, Breu M, Wimmer I, Kovacs G, Risser D, Klupp N, Simonitsch‐Klupp I, Roetzer T, Rommer P, Berger T, Gelpi E, Lassmann H, Graus F, Dalmau J, Höftberger R (2021) Neuropathological variability within a spectrum of NMDAR‐encephalitis. Ann Neurol, : 2021 Sep 25. doi: 10.1002/ana.26223. Online ahead of print.
  • Weinhofer I, Rommer P, Zierfuss B, Altmann P, Foiani M, Heslegrave A, Zetterberg H, Gleiss A, Musolino P, Gong Y, Forss-Petter S, Berger T, Eichler F, Aubourg P, Köhler W, Berger J (2021) Neurofilament light chain as a potential biomarker for monitoring neurodegeneration in X-linked adrenoleukodystrophy Nat Commun, 12 (1)
  • Dal-Bianco A, Grabner G, Kronnerwetter C, Weber M, Kornek B, Kasprian G, Berger T, Leutmezer F, Rommer P, Trattnig S, Lassmann H, Hametner S (2021) Long-term evolution of multiple sclerosis iron rim lesions in 7 T MRI Brain, 144(3): 833-847
  • Zrzavy T, Schwaiger C, Wimmer I, Berger T, Bauer J, Butovsky O, Schwab J, Lassmann H, Höftberger R (2021) Acute and non-resolving inflammation associate with oxidative injury after human spinal cord injury Brain, 144(1): 144-161
  • Wimmer I, Scharler C, Kadowaki T, Hillebrand S, Scheiber‐Mojdehkar B, Ueda S, Bradl M, Berger T, Lassmann H, Hametner S (2021) Iron accumulation in the choroid plexus, ependymal cells and CNS parenchyma in a rat strain with low‐grade haemolysis of fragile macrocytic red blood cells Brain Pathol, 31(2): 333-345
    | Weblink |

2021 Reviews

  • Dal-Bianco A, Höftberger R, Lassmann H, Berger T (2021) Kurt Jellinger 90: his contribution to neuroimmunology J Neural Transm, 128(10): 1545-1550

2020 Original Articles

  • Zamarian L, Berger T, Pertl M, Bsteh G, Djamshidian A, Deisenhammer F, Delazer M (2020) Decision making and framing effects in multiple sclerosis Eur J Neurol, 28 (4): 1292-1298
  • Monschein T, Salhofer-Polanyi S, Altmann P, Zrzavy T, Dal-Bianco A, Bsteh G, Rommer P, Berger T, Leutmezer F (2020) Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis J Neurol, 268 (4): 1247-1253
  • Zrzavy T, Wimmer I, Rommer P, Berger T (2020) Immunology of COVID‐19 and disease‐modifying therapies: the good, the bad and the unknown Eur J Neurol,